Free Trial
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free KLDO Stock Alerts

Kaleido Biosciences (KLDO) Competitors

Kaleido Biosciences logo
$0.0001 0.00 (0.00%)
As of 06/10/2026 02:40 PM Eastern
Compare

KLDO vs. PRST, DMN, ICCT, GROM, and KBNT

Should you buy Kaleido Biosciences stock or one of its competitors? MarketBeat compares Kaleido Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kaleido Biosciences include Presto Automation (PRST), Grafiti (DMN), iCoreConnect (ICCT), Grom Social Enterprises (GROM), and Kubient (KBNT). These companies are all part of the "computer software" industry.

How does Kaleido Biosciences compare to Presto Automation?

Kaleido Biosciences (NASDAQ:KLDO) and Presto Automation (NASDAQ:PRST) are both small-cap computer software companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Kaleido Biosciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Presto Automation has a beta of -3.47, suggesting that its stock price is 447% less volatile than the broader market.

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Presto Automation'saverage media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
Presto Automation Neutral

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Presto Automation N/A N/A N/A

81.6% of Kaleido Biosciences shares are owned by institutional investors. Comparatively, 20.9% of Presto Automation shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by company insiders. Comparatively, 10.0% of Presto Automation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Presto Automation has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Presto Automation, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Presto Automation$19.05M0.00-$34.48M-$1.23N/A

Summary

Presto Automation beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Grafiti?

Kaleido Biosciences (NASDAQ:KLDO) and Grafiti (NASDAQ:DMN) are both small-cap computer software companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Grafiti has lower revenue, but higher earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Grafiti, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Grafiti$386.09K0.02-$45.95M-$84.00N/A

81.6% of Kaleido Biosciences shares are held by institutional investors. Comparatively, 11.7% of Grafiti shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by insiders. Comparatively, 0.3% of Grafiti shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Grafiti'saverage media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
Grafiti Neutral

Kaleido Biosciences has a net margin of 0.00% compared to Grafiti's net margin of -874.43%. Kaleido Biosciences' return on equity of 0.00% beat Grafiti's return on equity.

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Grafiti -874.43%-1,561.96%-160.38%

Kaleido Biosciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Grafiti has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

Summary

Kaleido Biosciences beats Grafiti on 7 of the 11 factors compared between the two stocks.

How does Kaleido Biosciences compare to iCoreConnect?

iCoreConnect (NASDAQ:ICCT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Kaleido Biosciences has a net margin of 0.00% compared to iCoreConnect's net margin of -263.12%. Kaleido Biosciences' return on equity of 0.00% beat iCoreConnect's return on equity.

Company Net Margins Return on Equity Return on Assets
iCoreConnect-263.12% -1,451.73% -171.32%
Kaleido Biosciences N/A N/A N/A

13.4% of iCoreConnect shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 59.4% of iCoreConnect shares are held by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

iCoreConnect has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than iCoreConnect, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iCoreConnect$11.05M0.00-$15.55M-$44.40N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

iCoreConnect has a beta of 33.29, indicating that its share price is 3,229% more volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

In the previous week, iCoreConnect's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
iCoreConnect Neutral
Kaleido Biosciences Neutral

Summary

Kaleido Biosciences beats iCoreConnect on 6 of the 11 factors compared between the two stocks.

How does Kaleido Biosciences compare to Grom Social Enterprises?

Grom Social Enterprises (NASDAQ:GROM) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Company Net Margins Return on Equity Return on Assets
Grom Social EnterprisesN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

15.9% of Grom Social Enterprises shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 0.0% of Grom Social Enterprises shares are owned by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Grom Social Enterprises has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Grom Social Enterprises has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Grom Social Enterprises, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grom Social Enterprises$3.72M0.00-$12.53M-$11.67N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

In the previous week, Grom Social Enterprises' average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Grom Social Enterprises Neutral
Kaleido Biosciences Neutral

Summary

Grom Social Enterprises and Kaleido Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Kaleido Biosciences compare to Kubient?

Kaleido Biosciences (NASDAQ:KLDO) and Kubient (NASDAQ:KBNT) are both small-cap computer software companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Kaleido Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Kubient has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

81.6% of Kaleido Biosciences shares are owned by institutional investors. Comparatively, 13.9% of Kubient shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by company insiders. Comparatively, 22.3% of Kubient shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kubient has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Kubient, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Kubient$1.17M0.00-$13.62M-$0.17N/A

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Kubient'saverage media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
Kubient Neutral

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Kubient N/A N/A N/A

Summary

Kubient beats Kaleido Biosciences on 5 of the 7 factors compared between the two stocks.

Get Kaleido Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLDO vs. The Competition

Export
MetricKaleido BiosciencesBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$4K$446.64M$6.47B$11.73B
Dividend YieldN/A3.86%2.67%5.56%
P/E Ratio0.003.1524.4324.35
Price / Sales0.006,359.12503.66108.32
Price / CashN/A13.1343.2054.62
Price / BookN/A86.2310.506.82
Net Income-$95.48M-$96.07M$3.56B$337.41M
7 Day PerformanceN/A-1.54%0.23%2.29%
1 Month PerformanceN/A-0.46%0.67%3.48%
1 Year PerformanceN/A49.77%22.17%27.16%

Kaleido Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLDO
Kaleido Biosciences
N/A$0.00
flat		N/AN/A$4K$1.10MN/A80
PRST
Presto Automation
N/AN/AN/AN/A$10K$19.05MN/A4
DMN
Grafiti
N/A$0.00
flat		N/AN/A$8K$386.09KN/AN/A
ICCT
iCoreConnect
N/A$0.00
flat		N/AN/A$5K$11.05MN/A41
GROM
Grom Social Enterprises
N/A$0.00
flat		N/A-88.9%$1K$3.72MN/A450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KLDO) was last updated on 6/12/2026 by MarketBeat.com Staff.
From Our Partners
Is your wealth prepared for “America’s Most Dangerous Man”? (Read before June 16)
60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...
Chaikin Analytics | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
OpenAI is preparing to go public
OpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...
InvestorPlace | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel